MEDICATION FOR ALCOHOLISM WITHDRAWAL
This article is about Medication For Alcoholism Withdrawal. In this article we are trying to provide you good information about Medication For Alcoholism Withdrawal. We have arranged the information in this post to make you understand it easily. We hope that you can understand it well. Please check the information below.
Medication For Alcoholism Withdrawal
In the United States there are four currently approved medications for alcoholism: disulfiram, two forms of naltrexone, and acamprosate. Several other drugs are also used and many are under investigation.
Acamprosate (Campral) may stabilise the brain chemistry that is altered due to alcohol dependence via antagonising the actions of glutamate, a neurotransmitter which is hyperactive in the post-withdrawal phase. By reducing excessive NMDA activity which occurs at the onset of alcohol withdrawal, acamprosate can reduce or prevent alcohol withdrawal related neurotoxicity. Acamprosate reduces the risk of relapse amongst alcohol dependent persons.
Benzodiazepines, while useful in the management of acute alcohol withdrawal, if used long-term can cause a worse outcome in alcoholism. Alcoholics on chronic benzodiazepines have a lower rate of achieving abstinence from alcohol than those not taking benzodiazepines. This class of drugs is commonly prescribed to alcoholics for insomnia or anxiety management. Initiating prescriptions of benzodiazepines or sedative-hypnotics in individuals in recovery has a high rate of relapse with one author reporting more than a quarter of people relapsed after being prescribed sedative-hypnotics. Those who are long-term users of benzodiazepines should not be withdrawn rapidly, as severe anxiety and panic may develop, which are known risk factors for relapse into alcohol abuse. Taper regimes of 6–12 months have been found to be the most successful, with reduced intensity of withdrawal.
Calcium carbimide (Temposil) works in the same way as disulfiram; it has an advantage in that the occasional adverse effects of disulfiram, hepatotoxicity and drowsiness, do not occur with calcium carbimide.
Disulfiram (Antabuse) prevents the elimination of acetaldehyde, a chemical the body produces when breaking down ethanol. Acetaldehyde itself is the cause of many hangover symptoms from alcohol use. The overall effect is severe discomfort when alcohol is ingested: an extremely fast-acting and long-lasting uncomfortable hangover. This discourages an alcoholic from drinking in significant amounts while they take the medicine.
Naltrexone is a competitive antagonist for opioid receptors, effectively blocking the effects of endorphins and opiates. Naltrexone is used to decrease cravings for alcohol and encourage abstinence. Alcohol causes the body to release endorphins, which in turn release dopamine and activate the reward pathways; hence when naltrexone is in the body there is a reduction in the pleasurable effects from consuming alcohol. Evidence supports a reduced risk of relapse among alcohol dependent persons and a decrease in excessive drinking. Nalmefene also appears effective and works by a similar manner.
The Sinclair method is a method of using opiate antagonists to treat alcoholism by having the person take the medication about an hour before they drink alcohol, and only then. The opioid blocks the positive reinforcement effects of ethanol and hopefully allows the person to stop drinking or drink less.
Evidence does not support the use of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), antipsychotics, or gabapentin.
So that is all about Medication For Alcoholism Withdrawal. We think that it is good information about Medication For Alcoholism Withdrawal. We hope that this information is useful for you. Please share if you think that this information can be useful for others. If you need more article related to Medication For Alcoholism Withdrawal you can simply subscribe this blog. Thanks for visiting and have a nice browsing.
National Institute on Alcohol Abuse and Alcoholism. http://pubs.niaaa.nih.gov/publications/AA76/AA76.htm
Mason BJ, Heyser CJ (January 2010). “The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence”. Expert Opin Drug Saf. 9 (1): 177–88. doi:10.1517/14740330903512943. PMID 20021295.
Mason BJ, Heyser CJ (March 2010). “Acamprosate: A prototypic neuromodulator in the treatment of alcohol dependence”. CNS Neurol Disord Drug Targets. 9 (1): 23–32. doi:10.2174/187152710790966641. PMC . PMID 20201812.
Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M (2010). Rösner S, ed. “Acamprosate for alcohol dependence”. Cochrane Database of Systematic Reviews (9): CD004332. doi:10.1002/14651858.CD004332.pub2. PMID 20824837.
Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC (14 May 2014). “Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings”. JAMA. 311 (18): 1889–900. doi:10.1001/jama.2014.3628. PMID 24825644.
Lindsay, S.J.E.; Powell, Graham E., eds. (28 July 1998). The Handbook of Clinical Adult Psychology (2nd ed.). Routledge. p. 402. ISBN 978-0-415-07215-1.
Gitlow, Stuart (1 October 2006). Substance Use Disorders: A Practical Guide (2nd ed.). USA: Lippincott Williams and Wilkins. pp. 52 and 103–121. ISBN 978-0-7817-6998-3.
Kushner MG, Abrams K, Borchardt C (March 2000). “The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings”. Clin Psychol Rev. 20 (2): 149–71. doi:10.1016/S0272-7358(99)00027-6. PMID 10721495.
Ogborne AC (June 2000). “Identifying and treating patients with alcohol-related problems”. CMAJ. 162(12): 1705–8. PMC . PMID 10870503.
Soyka M, Rösner S (November 2008). “Opioid antagonists for pharmacological treatment of alcohol dependence – a critical review”. Curr Drug Abuse Rev. 1(3): 280–91. doi:10.2174/1874473710801030280. PMID 19630726.
Anderson, Kenneth (Jul 28, 2013). “Drink Your Way Sober with Naltrexone”. Psychology Today. Retrieved 18 July 2016.
Sinclair, JD (2001). “Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism.”. Alcohol and alcoholism (Oxford, Oxfordshire). 36 (1): 2–10.